Valeant Pharma (VRX) Reports Q2 EPS of $1.91
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Rescue work underway after quakes rock Venezuela, 'high casualties' likely
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
Valeant (VRX) Price Target Reduced at Deutsche Bank
July 31, 2014 3:08 PM EDTDeutsche Bank maintained a Hold rating on Valeant Pharmaceuticals (NYSE: VRX) and reduced its price target to $128.00 (from $133.00). The change follows its Q2 report. Analyst Gregg Gilbert described results as "ho-hum."
"While EPS of $1.91 came in line with our estimate (helped by lower tax rate), gross margin, operating income, and cash flow came in under our... More
Valeant Pharma (VRX) price drop a buying opportunity, Bill Ackman tells CNBC
July 31, 2014 12:19 PM EDTValeant Pharma (NYSE: VRX) price drop a buying opportunity, Bill Ackman tells CNBC. Shares are down nearly 7.6% following results.
... More